Sun Pharma Share Price Target 2026 — Key Factors, Financial Performance & Analyst Forecast

Sun Pharmaceutical Industries is trading at Rs.1,660 as of April 2026, approximately 15% below its 52-week high of Rs.1,960. The correction reflects broad pharma sector caution — US pricing pressure on generics, FDA inspection overhang on some facilities, and slower specialty product uptake. Yet Sun Pharma’s share price target from analysts remains well above current levels, backed by a transforming specialty business in the US that now contributes over 35% of US revenues, and a dominant branded generics position in India.

This article covers SUNPHARMA’s current share price, the key drivers of price movement, Q3 FY26 financial performance, technical levels, institutional positioning, and the analyst share price target for 2026 and beyond.

About SUNPHARMA

Click Here – Get Free Investment Predictions

Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) is India’s largest pharmaceutical company and the fourth-largest specialty generic pharma company globally by revenue. Founded in 1983 by Dilip Shanghvi and headquartered in Mumbai, Sun Pharma has operations in over 100 countries and employs approximately 44,000 people globally. Its market cap of approximately Rs.3,98,000 crore makes it one of India’s top-15 listed companies.

Sun Pharma’s business is split across three segments: US generics and specialty (approximately 33% of revenue), India branded generics (approximately 30%), and RoW and Emerging Markets (approximately 37%). Its specialty portfolio in the US includes Ilumya (psoriasis), Cequa (dry eye disease), Winlevi (acne), and Leqvio (cholesterol) — high-margin biologics and novel drugs that are reshaping its revenue quality.

Key Factors Influencing SUNPHARMA Share Price in 2026

Tap to Access Best Research Pieces on SUNPHARMA on Univest

1. US Specialty Revenue Growing But Adoption Slower Than Expected

Sun Pharma’s US specialty business — anchored by Ilumya (psoriasis) and Cequa (dry eye) — is growing at 20-25% annually, but from a lower base than management’s 2023 guidance. The specialty business now contributes approximately 35% of US revenues (vs a target of 50%), and reaching 50% will take 2-3 more years.

2. US Generic Pricing Pressure

Sun Pharma’s US generics portfolio (approximately 65% of US revenue) faces persistent pricing pressure from competition. Generic prices decline 5-10% annually on average, requiring continuous new product launches to maintain revenues. The FDA’s drug shortage program has partially offset this, but the structural headwind remains.

3. India Business Dominant and Growing

Sun Pharma’s India branded generics business — with 30%+ market share in dermatology and a top-5 position in ophthalmology, cardiology, and CNS — grew approximately 10% in FY26. The India business is Sun Pharma’s most predictable segment, with consistent 10-12% annual revenue growth and the highest margins.

4. FDA Inspection Overhang at Halol Plant

Sun Pharma’s Halol facility (Gujarat) has historically faced USFDA inspection concerns. While the most recent inspection was satisfactory, any renewed FDA action would create near-term uncertainty for the stock’s specialty product approvals pipeline.

SUNPHARMA Latest News That Impacted the Stock

• November 2025: Sun Pharma Q2 FY26 results: Revenue Rs.13,262 crore (+11.5% YoY); PAT Rs.2,890 crore (+21.3% YoY); specialty revenue grew 28% in US. Stock rallied 4% post results.
• January 2026: Leqvio (inclisiran — cholesterol-lowering drug) approved for expanded use in India; Sun Pharma is the exclusive Indian marketing partner for Novartis’s Leqvio.
• February 2026: US FDA completes inspection of Sun Pharma’s Mohali facility with ‘no action indicated’ — positive signal for pipeline approvals.
• March 2026: US tariff uncertainty triggers pharma sector caution; analysts flag potential US generic tariff impact on Indian pharma companies including Sun Pharma.
• April 2026: Sun Pharma files NDA for MM-II (melanoma drug) with USFDA — potential new specialty blockbuster for FY28 launch.

SUNPHARMA Q3 FY26 Financial Performance

Here is a snapshot of recent financial performance to frame the share price target discussion:

Source: NSE/BSE filings, Company earnings release. Verify latest data on nseindia.com.

Track live metrics and peer comparison on the Univest Screener.

Technical Signals — Price Levels to Watch

The stock is trading at its current level, approximately 0x relative to its fundamentals. Key resistance is at the 52-week high, and support levels are defined by prior consolidation zones. Investors tracking the stock should monitor the 200-day moving average as a key trend indicator.

Download the Univest iOS App or Univest Android App to set live price alerts and receive SEBI-registered analyst research on SUNPHARMA.

Future Outlook — Key Catalysts

• US specialty revenue reaching 50% of US revenues by FY28 — at significantly higher margins than generics, driving EBITDA margin expansion to 30%+
• MM-II (melanoma drug) NDA approval in US — potential Rs.2,000-3,000 crore annual revenue addition by FY28
• India business growing 10-12% annually on chronic disease portfolio (diabetes, CVD, dermatology) — the most predictable segment
• US pharma tariff risk is a potential threat, but Sun Pharma’s US manufacturing presence partially mitigates the risk versus peers

Start Free Trial

SUNPHARMA Share Price Target 2026 — Analyst Consensus

Subscribe to Univest Pro for Premium SUNPHARMA Research and F&O Setups

Short-Term Target (3–6 months)

Rs.1,700-1,850 (3-6 months); Q3 FY26 full results and specialty revenue trajectory are key triggers.

12-Month Analyst Consensus Target

Rs.1,850-2,100 (12-month consensus); implies 11-26% upside. Morgan Stanley target Rs.2,100; Kotak Rs.1,950; Motilal Oswal Rs.1,850.

Long-Term Target (2027–2028)

Rs.2,300-2,700 (2027-28); predicated on US specialty at 50% of US revenue, MM-II approval, and EBITDA margin at 30%+.

Compare analyst targets for SUNPHARMA against peers on the Univest Screener.

FAQs

What is Sun Pharma share price target 2026?

The 12-month analyst consensus target for Sun Pharma is Rs.1,850-2,100 from Rs.1,660, implying 11-26% upside. Short-term target Rs.1,700-1,850. Long-term (2027-28), Rs.2,300-2,700 on specialty revenue reaching 50% of US sales.

What is Sun Pharma’s specialty business?

Sun Pharma’s US specialty portfolio includes Ilumya (psoriasis), Cequa (dry eye disease), Winlevi (acne), and Leqvio (cholesterol) — high-margin biologics and novel drugs. Specialty revenue grew 27.3% YoY in Q2 FY26 and now contributes approximately 35% of US revenues.

What is Sun Pharma’s India market position?

Sun Pharma is the number 1 pharma company in India by market share, with over 30% market share in dermatology and top-5 positions in ophthalmology, cardiology, CNS, and gynaecology. India branded generics (approximately 30% of revenue) grow at 10-12% annually.

Is there an FDA risk for Sun Pharma?

Sun Pharma’s Halol facility (Gujarat) historically faced FDA observations, but the most recent inspection was satisfactory. The Mohali facility received ‘no action indicated’ in February 2026. FDA inspection risk is an ongoing pharma sector consideration but is currently well-managed.

What is Sun Pharma EBITDA margin?

Sun Pharma’s EBITDA margin was 27.8% in Q2 FY26, up 190 bps YoY — driven by the shift toward higher-margin specialty drugs. Management targets 30%+ EBITDA margins over FY28-29 as specialty reaches 50% of US revenues.

What is Sun Pharma’s R&D pipeline?

Sun Pharma spends approximately 8% of revenues on R&D annually. Key pipeline assets include MM-II (melanoma), Deuruxolitinib (alopecia areata — under USFDA review), and several India-specific specialty launches. The MM-II NDA filed in April 2026 is the most significant near-term pipeline catalyst.

Will US pharma tariffs impact Sun Pharma?

US tariffs on generic pharma imports from India could be a headwind for Sun Pharma’s US generic business. However, Sun Pharma has some US manufacturing presence, and specialty drugs (biologics) are likely to be excluded from tariffs. The net impact depends on the final tariff structure.

What is Sun Pharma market cap?

Sun Pharma’s market cap is approximately Rs.3,98,000 crore as of April 2026, making it India’s largest pharmaceutical company by market cap. The stock trades at P/E of approximately 33x and is a Nifty 50 constituent.

This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of April 2026 and are subject to change. Investments in securities are subject to market risk. Please consult a SEBI-registered financial advisor before making any investment decisions.

Recent Article

Coal India Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

Bharti Airtel Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

State Bank of India Share Price Target 2026: Analyst Forecasts, Bull & Bear Case

Paytm Share Price Target 2026: Analyst Forecasts, Bull & Bear Case